Skip to main content
PACS logo

PACS · PACS Group, Inc.

Track PACS — free
$48.93 +0.61 (+1.25%)
Market Cap
$7.67B
Shares
158.72M
Volume · Nov 16 106.91K Avg daily vol (3M) 791.32K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$48.32 Open$48.32 Day$47.24–48.47 52W close$10.58–50.26 Avg vol 30d866K Short int4.3M · 2.7% of shares · 5.1d Short vol54% Last earningsNov 4, 2026 DataApr 2024–Nov 2026 Filing10-Q · Nov 3

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 4
Earnings call
Raises 2026 revenue and adjusted EBITDA guidance

PACS Group raised full-year 2026 revenue guidance to $5.95 billion to $6.05 billion and adjusted EBITDA guidance to $685 million to $695 million, citing strength in its existing portfolio and recent acquisitions.

3 source passages
For full year 2026, we are increasing our revenue guidance to $5.95 billion to $6.05 billion, and our adjusted EBITDA guidance to $685 million to $695 million. Our updated outlook reflects the continued strength of our existing portfolio and includes $5 million of EBITDA contributions from retroactive quality incentive payments in Ohio that we received in October. For a reconciliation of non-GAAP financial measures discussed during this call to the most directly comparable GAAP measure, please refer to the earnings release and the appendix included in the investor presentation, which are both published and available on the Investor Relations section of PACS Group's website. Open the document at this passage
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Net income rose as facility portfolio expanded

PACS Group, Inc. reported nine-month net income of $217,829 thousand versus $131,676 thousand, while skilled nursing services revenue reached $4,206,010 thousand. It operated 355 facilities across 20 states as of September 30, 2026.

Revenue $1.5B ▲ 11.5% Net income $60.82M ▲ 16.1% Diluted EPS $0.37 ▲ 15.6%
Read from the MD&A section
3 source passages
Net income | 60,812 | 52,330 | 217,829 | 131,676 Net income attributable to PACS Group, Inc. | 60,818 | 52,406 | 217,883 | 131,841 Skilled nursing services revenue | 2,748,007 | | 1,085,770 | | 372,233 | | 4,206,010 | As of September 30, 2026, our portfolio consisted of 355 post-acute care, assisted living, and independent living facilities across 20 states serving 34,700 patients daily. Open the document at this passage
Nov 3
Current report 8-K
Adjusted EBITDA guidance raised to $685 million to $695 million

PACS Group, Inc. increased full-year 2026 Adjusted EBITDA guidance to $685 million to $695 million and revenue guidance to $5.95 billion to $6.05 billion. Third-quarter revenue was $1.50 billion and Adjusted EBITDA was $175.7 million.

Financial results
5 source passages
PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, announced operating results for the third quarter of 2026. Revenue was $1.50 billion, an increase of 11.5% over prior year. Adjusted EBITDA was $175.7 million, an increase of $44.2 million, or 33.6% from $131.5 million in the prior-year period. “We are also increasing our revenue guidance to $5.95 billion to $6.05 billion, up from our prior range of $5.75 billion to $5.85 billion." “Given the continued excellent performance of our portfolio across all cohorts, we are increasing our full-year 2026 Adjusted EBITDA guidance to a range of $685 million to $695 million, up from our prior range of $640 million to $660 million,” said Hendrickson. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$5.71B
Trailing 12 months
Net income (TTM)
$277.58M
Trailing 12 months
Revenue growth YoY
+11.5%
Year over year
Operating margin
7.4%
Trailing 12 months
P / E (TTM)
27.5
Trailing earnings · reciprocal yield 3.6%
FCF yield
—
TTM · current market cap
Return on invested capital
21.6%
Trailing 12 months
Net cash
−$157.05M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-0.5%
Year over year · fewer shares
Price change (1Y)
+351.6%
Trailing year
Short interest
2.7%
Latest settlement · 5.1 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 4, 2026
Q3 FY26

TL;DR. PACS raised full-year revenue and adjusted EBITDA guidance while reporting strong third-quarter earnings, same-store growth, cash generation and geographic expansion. Risks include acquisition mix and integration investment, higher stock-based compensation, policy challenges involving rates, regulation and minimum staffing, ongoing government investigations and unresolved material weaknesses.

Bullish
  • + Full-year 2026 revenue guidance increased to $5.95 billion-$6.05 billion from $5.75 billion-$5.85 billion.
  • + Full-year 2026 adjusted EBITDA guidance increased to $685 million-$695 million from $640 million-$660 million.
  • + Third-quarter adjusted EBITDA increased 33.6% to $175.7 million from $131.5 million.
  • + Same-store skilled nursing revenue increased 6.4%, occupancy improved to 91.3% from 89.3%, and skilled mix increased.
  • + Nine-month operating cash flow reached $583.1 million, supported by $707.4 million of liquidity and 0.2x net leverage.
  • + Expansion into Florida and continued growth in Texas broadened the company's geographic reach and created new operating opportunities.
Bearish
  • − Newly acquired ADURAL facilities entered at lower occupancy and skilled mix, reducing certain consolidated averages.
  • − General and administrative expense increased to $138.4 million from $102.5 million, including higher stock-based compensation of $45.3 million versus $12.5 million.
  • − Newly acquired facilities require substantial upfront integration investment before operating improvements are realized.
  • − Government investigations remain ongoing, with their timing and ultimate outcomes unpredictable.
  • − Full remediation of material weaknesses still required effectiveness testing and confirmation by the end of 2026.
  • − Management highlighted potential policy challenges involving rates, regulation and minimum-staffing requirements.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +20%
above
Price vs 50-day avg +7%
above
RSI (14) 53
neutral
MACD trend Negative
52-week position 95%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +3%
trailing
6-month return +24%
trailing
YTD return +26%
this year
Relative strength +24%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $45 › 200d $40 — 50d above 200d
Institutional flow Accumulating
212 of 245 funds reported for Sep 30 · net +1.6M sh shares · +26 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.71% of shares out · ▼ -1.0% MoM · 5.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
245 holders — near 2-yr high, broad support
Squeeze score 60
elevated · 0–100
Fundamentals
Excellent
Revenue growth +29%
Y/Y
EPS growth +221%
Y/Y
Valuation P/E 27.6
in line
Buyback $250.0M
remaining
Balance sheet $52.3M
net debt
Quant / Vol
risk profile
Very High
Volatility 93%
annualized · 1-yr
Max drawdown −28%
past year
ATR 4.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 2 of last 2
Latest guidance · from the Earnings Call filed Aug 5, 2026
Full-year revenue · full year 2026 Maintained $5.75B – $5.85B
Aug 4, 2026 $5.75B – $5.85B changed to Aug 5, 2026 $5.75B – $5.85B
prior FY $5.29B midpoint +9.7% Y/Y
Adjusted EBITDA · full year 2026 Non-GAAP Maintained $640M – $660M
Aug 4, 2026 $640M – $660M changed to Aug 5, 2026 $640M – $660M
Prior guidance period ended · from the 8-K filed Nov 19, 2025
Revenue · full year 2025 $5.25B – $5.35B
Adjusted EBITDA · full year 2025 $480M – $490M
Guided vs delivered · last 2 settled
Revenue full year 2025
guided $5.25B – $5.35B
$5.29B In line
Revenue full year 2024
guided $3.85B – $3.95B
$4.09B Beat +4.9%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+20% Bullish
Price vs 50-day avg
+7% Bullish
RSI (14)
53 Neutral
MACD trend
Negative Bearish
52-week position
95% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $45 › 200d $40 — 50d above 200d
Institutional flow Accumulating
212 of 245 funds reported for Sep 30 · net +1.6M sh shares · +26 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.71% of shares out · ▼ -1.0% MoM · 5.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
245 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $11 Now $48 · 95% Range high $50
vs 200-day avg +20% vs 50-day avg +7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Actual patient days 2,640,144 the three months ended June 30, 2026 filing —
Adjusted Earnings Per Share non-GAAP $0.63 the second quarter of 2026 —
Adjusted EBITDA non-GAAP $337.14M Six Months Ended June 30, 2026 —
Adjusted EBITDAR non-GAAP 261.5M the second quarter of 2026 —
GAAP → non-GAAP reconciliation
Adjusted EBITDA 166.75M (non-GAAP)
+94.7M Rent - cost of services
= Adjusted EBITDAR 261.45M
Adjusted Net Income non-GAAP $101.73M Three Months Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP Net income attributable to PACS Group, Inc. 76.37M
+734K Acquisition related costs
+25.83M Stock-based compensation expense
+8.17M Legal and other costs
-9.38M Provision for income taxes on non-GAAP adjustments
= Adjusted Net Income 101.73M
Available liquidity 756.6M June 30, 2026 —
Average daily rate - Medicaid (Total) $342.98 Three Months Ended June 30, 2026 —
Average daily rate - Medicare (Total) $956.75 Three Months Ended June 30, 2026 —
Average daily rate - Total $505.35 Six Months Ended June 30, 2026 —
EBITDA non-GAAP $132.02M Three Months Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP Net income attributable to PACS Group, Inc. 76.37M
+6.04M Interest expense
+29.49M Provision for income taxes
+20.12M Depreciation and amortization
= EBITDA 132.02M
Mature facilities average CMS star rating 4.5 the second quarter of 2026 —
Mature facilities occupancy 93.8% the second quarter of 2026 —
Mature facilities skilled mix 31.9% the second quarter of 2026 —
Non-cash rent expense 10.21M the three months ended June 30, 2026 filing —
Number of facilities at period end 284 Three Months Ended June 30, 2026 —
Number of operational beds at period end 32,790 Three Months Ended June 30, 2026 filing —
Occupancy 90.6% the second quarter of 2026 —
Occupancy rate (operational beds) 90.4% Three Months Ended June 30, 2026 —
Operating healthcare facilities 344 As of today —
Overall occupancy 90.4% the second quarter of 2026 —
Overall skilled mix 30% the second quarter of 2026 —
Patients served daily 33,400 current —
Real estate investment 190.8M the first six months of 2026 —
Same-store occupancy 90.6% the three months ended June 30, 2026 filing —
Same-store skilled mix by patient days 29.7% the three months ended June 30, 2026 filing —
Share of skilled nursing portfolio rated 4 or 5 stars 83.6% the second quarter of 2026 —
Skilled mix by nursing patient days 30% Three Months Ended June 30, 2026 filing —
Skilled mix by revenue 50% Three Months Ended June 30, 2026 —
Skilled nursing facilities rated 4 or 5 stars 239 the second quarter of 2026 —
Skilled nursing services revenue $2.75B Six Months Ended June 30, 2026 —
Skilled nursing services revenue (same-store) $2.69B Six Months Ended June 30, 2026 —
Skilled nursing services revenue change (same-store) 6.9% Six Months Ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Care Facilities — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PACS
PACS Group, Inc.
this stock
$7.67B +25.9% +29.3% 27.6 2.7%
HCA
HCA Healthcare, Inc.
$104.25B +6.9% +7.1% 16.6 2.3%
FSNUY
Fresenius SE & Co. KGaA
$33.34B +3.3% — — 0.0%
THC
Tenet Healthcare Corp
$22.76B +43.9% +0.9% 8.3 2.2%
EHC
Encompass Health Corp
$13.83B +32.8% +10.5% 22.0 3.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
254
% held
32.2%
Reported
212 of 245
Top holder
COHEN & STEERS, INC.
Held Float
View
Held by Funds
Fund positions
278
View
Short & Settlement
Short Interest Falling
Shares short
4.3M
Days to cover
5.1d
Change
-41.3K sh
View
Short Volume
Short vol %
54%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
70
Value
$3.4K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
42.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$5.3B
Net income (FY)
$191.5M
EPS diluted
$1.22
View
Buybacks
Authorized
$250.0M
Remaining
$250.0M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 3, 2026
This year
16

PACS Group, Inc. reported nine-month net income of $217,829 thousand versus $131,676 thousand, while skilled nursing services revenue reached $4,206,010 thousand. It operated 355 facilities across 20 states as of September 30, 2026.

View
Proposed Sales
Value
$9.4M
Shares
186.7K
Filed
Nov 4, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 4, 2026
View
Investor Relations
Latest news
Fifty-Eight PACS Post-Acute Locat…
Published
Nov 10, 2026
View

Performance

5D 20D 120D MTD YTD
PACS -2.6% +3.0% +24.3% +1.1% +25.9%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -5.2% +4.2% +23.8% +1.3% +15.3%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$250.00M
Spent (derived)
$0
Remaining
$250.00M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 2001184 CUSIP 69380Q107 13F (30d) 191 filings 175 filers Visit website Investor relations